Table 4.

Treatment-emergent adverse events (TEAEs)

TEAE	Number of patients (%)*
	Placebo (n=51)	Fasinumab
		0.1 mg/kg (n=53)	0.3 mg/kg (n=54)	All doses (n=107)
Any TEAE	23 (45.1)	27 (50.9)	35 (64.8)	62 (57.9)
Serious TEAEs	1 (2.0)	1 (1.9)	2 (3.7)	3 (2.8)
TEAEs resulting in study discontinuation	0	1 (1.9)	0	1 (1.9)
Treatment-related TEAEs	6 (11.8)	7 (13.2)	13 (24.1)	20 (18.7)
Most common TEAEs, occurring in ≥2% of combined fasinumab doses
Paresthesia	0	1 (1.9)	10 (18.5)	11 (10.3)
Arthralgia	3 (5.9)	2 (3.8)	8 (14.8)	10 (9.3)
Pain in extremity	1 (2.0)	0	8 (14.8)	8 (7.5)
Headache	2 (3.9)	2 (3.8)	5 (9.3)	7 (6.5)
Anxiety	0	2 (3.8)	3 (5.6)	5 (4.7)
Nausea	1 (2.0)	3 (5.7)	2 (3.7)	5 (4.7)
Upper respiratory tract infection	3 (5.9)	1 (1.9)	4 (7.4)	5 (4.7)
Nasopharyngitis	1 (2.0)	1 (1.9)	3 (5.6)	4 (3.7)
Decreased vibratory sense	1 (2.0)	2 (3.8)	1 (1.9)	3 (2.8)
Dizziness	1 (2.0)	2 (3.8)	1 (1.9)	3 (2.8)
Hypoesthesia	0	1 (1.9)	2 (3.7)	3 (2.8)
Muscle spasms	0	0	3 (5.6)	3 (2.8)
Myalgia	0	2 (3.8)	1 (1.9)	3 (2.8)
Urinary tract infection	1 (2.0)	2 (3.8)	1 (1.9)	3 (2.8)

Note:

^*Safety analysis set.